Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 31 Jul 2018 Planned End Date changed from 30 Dec 2019 to 31 Dec 2019.
- 26 Feb 2018 Status changed from active, no longer recruiting to recruiting.
- 05 Feb 2018 Planned End Date changed from 1 Jan 2020 to 30 Dec 2019.